Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J.R., Braunstein, J.B., Sabbagh, M., Bittner, T., Pontecorvo, M., Bozeat, S., Dage, J.L., Largent, E., Mattke, S., Correa, O., Robledo, L.M. Gutierrez, Baldivieso, V., Willis, D.R., Atri, A., Bateman, R.J., Ousset, P-J., Vellas, B., Weiner, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683846/
https://www.ncbi.nlm.nih.gov/pubmed/36281661
http://dx.doi.org/10.14283/jpad.2022.85

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683846/
https://www.ncbi.nlm.nih.gov/pubmed/36281661
http://dx.doi.org/10.14283/jpad.2022.85

Ejemplares similares